Africa and Middle East Cardiovascular Epidemiological Study

Obesity Clinical Trial

— ACE  

Official title:

Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01243138
• Other study ID #: A2581186
• Status: Completed
• Start date: July 2011
• Est. completion date: April 2012

Study information

• Verified date: February 2021
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.

Description:

This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained. Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4386
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult aged 18 or above

Exclusion Criteria:

• Pregnant women and/or lactating mothers
• Subjects presenting with any life threatening disease/condition

Related Conditions & MeSH terms

• Diabetes Mellitus
• Dyslipidemia
• Dyslipidemias
• Hypertension
• Obesity
• Smoking

Locations

Country	Name	City	State
Algeria	Pfizer Investigational Site	Alger
Algeria	Pfizer Investigational Site	Bejaja
Algeria	Pfizer Investigational Site	Djelfa
Algeria	Pfizer Investigational Site	Laghouat
Algeria	Pfizer Investigational Site	M'Sila
Algeria	Pfizer Investigational Site	Relizane
Algeria	Pfizer Investigational Site	Saida
Algeria	Pfizer Investigational Site	Tebessa
Algeria	Pfizer Investigational Site	Tlemcen
Cameroon	Pfizer Investigational Site	Bafoussam
Cameroon	Pfizer Investigational Site	Douala	Deido
Cameroon	Pfizer Investigational Site	Mbandjock
Cameroon	Pfizer Investigational Site	Njombe
Cameroon	Pfizer Investigational Site	Soa
Cameroon	Pfizer Investigational Site	Yaounde	Cite Verte
Egypt	Pfizer Investigational Site	Alexandria
Egypt	Pfizer Investigational Site	Cairo
Egypt	Pfizer Investigational Site	Shiben Al Kom
Egypt	Pfizer Investigational Site	Tanta
Ghana	Pfizer Investigational Site	Accra
Ghana	Pfizer Investigational Site	Jachie-Ashanti
Ghana	Pfizer Investigational Site	Kumasi
Ghana	Pfizer Investigational Site	Sogakope V/R
Ghana	Pfizer Investigational Site	Takoradi
Jordan	Pfizer Investigational Site	Amman
Jordan	Pfizer Investigational Site	Irbid
Jordan	Pfizer Investigational Site	Salt
Kenya	Pfizer Investigational Site	Chongoria
Kenya	Pfizer Investigational Site	Nairobi
Kuwait	Pfizer Investigational Site	Adailiya
Kuwait	Pfizer Investigational Site	Fahaheel
Kuwait	Pfizer Investigational Site	Kuwait
Kuwait	Pfizer Investigational Site	Mishref
Kuwait	Pfizer Investigational Site	Qadesya
Kuwait	Pfizer Investigational Site	Yarmouk
Lebanon	Pfizer Investigational Site	Beirut
Lebanon	Pfizer Investigational Site	Jbeil, Lebanon
Lebanon	Pfizer Investigational Site	Jounieh
Lebanon	Pfizer Investigational Site	Tripoli
Nigeria	Pfizer Investigational Site	Abuja, FCT
Nigeria	Pfizer Investigational Site	Abuja, Garki
Nigeria	Pfizer Investigational Site	Calabar
Nigeria	Pfizer Investigational Site	Enugu
Nigeria	Pfizer Investigational Site	Keffi, Nassarawa
Saudi Arabia	Pfizer Investigational Site	Dammam
Saudi Arabia	Pfizer Investigational Site	Jeddah
Saudi Arabia	Pfizer Investigational Site	Jeddah 21573
Saudi Arabia	Pfizer Investigational Site	Makkah
Saudi Arabia	Pfizer Investigational Site	Riyadh
Saudi Arabia	Pfizer Investigational Site	Riyadh
Saudi Arabia	Pfizer Investigational Site	Yanbu
Senegal	Pfizer Investigational Site	Dakar	Nabil Choucair
Senegal	Pfizer Investigational Site	Dakar	Ouakam
Senegal	Pfizer Investigational Site	Kebemer
Senegal	Pfizer Investigational Site	Kedoungou
Senegal	Pfizer Investigational Site	Saint Louis
Senegal	Pfizer Investigational Site	Ziguinchor
South Africa	Pfizer Investigational Site	Halfway House	Gauteng
South Africa	Pfizer Investigational Site	Kwa-Zulu Natal
South Africa	Pfizer Investigational Site	Mamelodi East	Pretoria
South Africa	Pfizer Investigational Site	Mokopane	Limpopo
South Africa	Pfizer Investigational Site	Rondebosch
South Africa	Pfizer Investigational Site	Sheshego	Limpopo
South Africa	Pfizer Investigational Site	Sydenham, Durban	Kwazulu-natal
Tunisia	Pfizer Investigational Site	Ariana
Tunisia	Pfizer Investigational Site	Bouficha
Tunisia	Pfizer Investigational Site	Messaadine
Tunisia	Pfizer Investigational Site	Sfax
Tunisia	Pfizer Investigational Site	Tunis
Tunisia	Pfizer Investigational Site	Zaghouan
United Arab Emirates	Pfizer Investigational Site	Abu Dhabi
United Arab Emirates	Pfizer Investigational Site	Al Ain
United Arab Emirates	Pfizer Investigational Site	Dubai
United Arab Emirates	Pfizer Investigational Site	Ras Al Khaima

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

Algeria,  Cameroon,  Egypt,  Ghana,  Jordan,  Kenya,  Kuwait,  Lebanon,  Nigeria,  Saudi Arabia,  Senegal,  South Africa,  Tunisia,  United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension		At the time of the first visit
Secondary	Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.		At the time of the first visit
Secondary	Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.		At the time of the first visit
Secondary	Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.		At the time of the first visit
Secondary	Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.		At the time of the first visit
Secondary	Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.		At the time of the first visit

External Links

•   To obtain contact information for a study center near you, click here.